ClinicalTrials.gg
RecruitingNCT07489443PICTUReUpdated Jul 6, 2026

Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum

An interventional study of Perinatal smoking cessation treatment and maintenance sessions in Perinatal, Cannabis Use and Tobacco Use, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.

Planned enrollment
257th of 288
25 · median 120
Started
2026
with 13 others
No phase
233 of 313
40 open now
Primary completion
2027-04
later than 27 of 64 live
Registered
301st of 313
by date

Among the 313 studies in Tobacco Use with a site in United States, this one is the 257th largest by planned enrollment of the 288 interventional ones that give a count, is one of 14 that started in 2026, is one of 233 with no phase, reaches primary completion later than 27 of the 64 other live ones, and was the 301st registered.

Tobacco Use

423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.

Browse Tobacco Use studies →

Open to participants now

54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Tobacco Use with a site in United States, or all of them as a file.
02

Study summary

Using both tobacco and cannabis during pregnancy is more common in minoritized groups and can make quitting smoking in pregnancy and remaining smoke free postpartum difficult. Investigators will test an intervention to address prenatal depressive symptoms to encourage people to quit tobacco and cannabis during pregnancy and stay quit postpartum.

03

Conditions studied

  • Perinatal
  • Cannabis Use
  • Tobacco Use
  • Smoking Cessation

Keywords

  • tobacco
  • perinatal
  • pregnancy
  • smoking
  • cessation
  • postpartum
  • cannabis
  • intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed pregnant
  • Under 26 weeks gestation
  • Plan to remain pregnant
  • English speaking
  • Use of combustible tobacco at least once a week during pregnancy, or at least once a week in the 3 months before pregnancy if stopped
  • Use of cannabis at any frequency during pregnancy or in the 3 months before pregnancy if stopped

Exclusion criteria

Exclusion Criteria:

  • Current opioid use or active treatment for Opioid Use Disorder
  • Unable to provide in English
  • Under 18 years old
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Feasibility and Acceptability Trial

    Behavioral: Perinatal smoking cessation treatment and maintenance sessions

Interventions

  • BehavioralPerinatal smoking cessation treatment and maintenance sessions

    Participants will meet one-on-one with a study interventionist over the course of 6 prenatal treatment sessions and 3 postpartum maintenance sessions. Sessions will include education and discussion on self-monitoring of targets/ problem identification, psychoeducation, behavioral activation, cognitive restructuring, and mindfulness skills.

06

What researchers measure

Primary outcomes

  1. Attendance

    Rate of attendance will be measured by proportion of sessions attended to total available sessions.

    Time frame: From enrollment to 3 months postpartum

  2. Completion of Intervention-Related Procedures

    Participant will complete activities designed to help them self-monitor their smoking-related behaviors during and between scheduled treatment sessions. Completion of activities will be measured by the proportion of completed activities to the total number of assigned activities.

    Time frame: From enrollment to 3 months postpartum

  3. Acceptability of the Intervention

    Participants' acceptance of the intervention will be measured using the Acceptability of Intervention Measure (AIM) at the 3-month postpartum assessment. This is a 4-item questionnaire with a scale range of 4-20, with a higher score indicating greater acceptance.

    Time frame: From enrollment to 3 months postpartum

Secondary outcomes

  1. Abstinence from Tobacco Products

    Abstinence from tobacco products will be measured by proportion of the participants who self-report no use of tobacco and by calculating the proportion of participants with negative urine screens for cotinine at the 3-month postpartum assessment.

    Time frame: Baseline assessment to 3 months postpartum

  2. Abstinence from Cannabis Products

    Abstinence from cannabis products will be measured by proportion of the participants who self-report no use of cannabis and by calculating the proportion of participants with negative urine screens for THC at the 3-month postpartum assessment.

    Time frame: Baseline assessment to 3 months postpartum.

  3. Depressive Symptoms from Baseline

    Change in depressive symptoms will be measured through self-report Edinburgh Postnatal Depression Scale (EPDS) at baseline assessment, pre-delivery treatment session, and 1 and 3 months postpartum assessments. The scale range is 0-30, with a higher score indicating higher depression.

    Time frame: Baseline assessment to 3 months postpartum

  4. Change in Tobacco Use from Baseline

    Change in tobacco use from baseline will be measured through a self-reported smoking questionnaire given at baseline assessment, pre-delivery treatment session, and 1 and 3 months postpartum assessments.

    Time frame: Baseline assessment to 3 months postpartum

  5. Change in Cannabis Use from Baseline

    Change in cannabis use from baseline will be measured through a self-reported smoking questionnaire given at baseline assessment, pre-delivery treatment session, and 1 and 3 months postpartum assessments.

    Time frame: Baseline assessment to 3 months postpartum

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — This is a small pilot trial and at this time we do not anticipate the need to share IPD to support efficient clinical research and bring benefit to patients. However, if in the conduct of the trial our understanding changes, we will revise our IPD plan.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 24, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07489443
Responsible party
Natacha DeGenna (Associate Professor of Psychiatry, Epidemiology, Clinical and Translational Science, University of Pittsburgh) — Principal investigator
First posted
Mar 24, 2026
Start date
Jun 17, 2026
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Project Coordinator
Contact
parentas@upmc.edu
412-301-3848
Natacha De Genna
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion